Japanese Single-Center Experience of Kidney Transplant: Experience in a Japanese Private Hospital

Transplant Proc. 2022 Mar;54(2):282-285. doi: 10.1016/j.transproceed.2021.09.074. Epub 2022 Jan 14.

Abstract

Background: We reviewed the results of cases of kidney transplant (KTx) that were conducted at the Toda Chuo General Hospital, a private hospital located in Saitama, Japan.

Methods: A total of 312 patients with end-stage renal failure underwent KTx between January 1992 and December 2019 at Toda Chuo General Hospital. There were 191 men and 121 women. Their mean age was 45.7 years. Of the 312 cases, 310 were living-related KTx, while 2 were deceased donor KTx. The immunosuppressive treatment protocol mainly consisted of 4-drug therapy with methylprednisolone, tacrolimus, mycophenolate mofetil, and basiliximab.

Results: Patient survival was 99.7% at 1 year, 99.3% at 5 years, and 97.3% at 10 years. Renal allograft survival was 98.4% at 1 year, 91.7% at 5 years, and 86.5% at 10 years. However, death-censored renal allograft survival was 98.7% at 1 year, 92.4% at 5 years, and 89.0% at 10 years. Among the 312 patients, 33 grafts were lost during the observation period. The loss was because of chronic antibody-mediated rejection in 19 patients, death with function in 6 patients, and acute antibody-mediated rejection in 2 patients.

Conclusions: The prognosis of patients and their grafts, which were managed following the immunosuppression protocol at our institute, was relatively good. KTx in a private hospital in Japan is at par with the global standard.

MeSH terms

  • Basiliximab
  • Female
  • Graft Rejection / prevention & control
  • Hospitals, Private
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Japan
  • Kidney Transplantation* / methods
  • Male
  • Middle Aged
  • Mycophenolic Acid / therapeutic use
  • Tacrolimus / therapeutic use

Substances

  • Immunosuppressive Agents
  • Basiliximab
  • Mycophenolic Acid
  • Tacrolimus